tiprankstipranks

Cryoport upgraded to Buy from Neutral at UBS

UBS upgraded Cryoport (CYRX) to Buy from Neutral with a $10 price target UBS believes that scaling cell and gene therapy service offerings provide a credible pathway to low-double-digit-plus mid- to long-term sales growth and positive free cash flow, the analyst tells investors in a research note. Challenges like broader biopharma market weakness and headwinds in MVE are well understood, appear to be stabilizing, and provide an attractive entry point, the firm says.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue